Novasenta: Funding, Investors & Team (Aug 2026)
Novasenta develops treatments to transform the lives of patients with cancer. It uses systematic, rigorous, and unbiased human tumor microenvironment analysis to uncover new druggable targets, exploiting the critical interplay of disease, immune response, and metabolism. Single-cell level analysis of high-quality, human tumor samples combined with the advanced data mining abilities of our research and computational biology teams accelerate the path from discovery to patient. The company aims to identify novel targets to generate effective therapies for various cancers. It was founded in 2018 and is headquartered in Pittsburgh, Pennsylvania.
Novasenta has raised $15.0M across 1 funding round on record, the most recent an undisclosed round of $15.0M announced in Feb 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Novasenta Company Profile and Key Stats
Latest funding round on record: Feb 2024.
Novasenta Funding Rounds
Novasenta Founders and Leadership Team
Contact details for the Novasenta team: 1 of 1 has an email address on file.
Start 14-day free trial →Novasenta Funding Compared to Other Biotechnology Startups
Novasenta's latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Novasenta in Biotechnology and Pittsburgh
Companies Similar to Novasenta
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Novasenta Funding FAQs
What does Novasenta do?
Novasenta develops treatments to transform the lives of patients with cancer. It uses systematic, rigorous, and unbiased human tumor microenvironment analysis to uncover new druggable targets, exploiting the critical interplay of disease, immune response, and metabolism. Single-cell level analysis of high-quality, human tumor samples combined with the advanced data mining abilities of our research and computational biology teams accelerate the path from discovery to patient. The company aims to identify novel targets to generate effective therapies for various cancers. It was founded in 2018 and is headquartered in Pittsburgh, Pennsylvania.
How much funding has Novasenta raised?
Novasenta has raised $15.0M across 1 round on record. The most recent is an undisclosed round of $15.0M announced in Feb 2024.
When did Novasenta last raise funding?
Novasenta's most recent funding round on record is an undisclosed round of $15.0M, announced in Feb 2024.
Who founded Novasenta?
FundedIQ lists Robert Ferris (Founder) at Novasenta.
Where is Novasenta headquartered?
Novasenta is based in Pittsburgh, Pennsylvania, United States.
How many employees does Novasenta have?
Novasenta is in the 11-50 employee band.
How does Novasenta's funding compare to other Biotechnology startups?
Novasenta's latest round of $15.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Novasenta Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Novasenta is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.